Nephros (Nephros) Total Stockholders Equity : $8.36 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Nephros Total Stockholders Equity?

Nephros's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $8.36 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Nephros's Book Value per Share for the quarter that ended in Dec. 2023 was $0.79. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Nephros's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.22.

Nephros Total Stockholders Equity Historical Data

The historical data trend for Nephros's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nephros Total Stockholders Equity Chart

Nephros Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

4.68

12.52

11.70

5.59

8.36

Nephros Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															5.59	8.89	8.66	8.62	8.36

Nephros (NAS:NEPH) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Nephros's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(8.358	-	0)	/	10.5437
	=	0.79

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Nephros's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.446	+	1.39)	/	8.358
	=	0.22

Nephros Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Nephros's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nephros (Nephros) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nephros Inc (NAS:NEPH) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

NPJP:Germany

Address

380 Lackawanna Place, South Orange, NJ, USA, 07079

Website

https://www.nephros.com

Nephros Inc is a commercial-stage company that develops and sells high performance water solutions to the medical and commercial markets. In medical markets, it sell water filtration products and waterborne pathogen detection products. In commercial markets, the company manufacture and sell water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The operating segments of the group are Water Filtration, Pathogen Detection and Renal Products of which key revenue is derived from Water Filtration segment.

Executives

Banks Robert R. Jr.	director, officer: President and CEO	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Judy Krandel	officer: Chief Financial Officer	320 W. 37TH STREET, 13TH FLOOR, NEW YORK NY 10018
Joseph Michael Harris	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Wesley S. Lobo	officer: Chief Marketing Officer	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Tom Gwydir	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Andrew Astor	officer: Chief Financial Officer	380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Charles E Davidson	director, 10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp	director, 10 percent owner	777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs	director, 10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Gp Llc	director, 10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH CT 33401
Oliver J. Spandow	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daniel S. D'agostino	officer: Chief Financial Officer	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daron Evans	director, officer: President and CEO	C/O NEPHROS, INC., 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Alisa Lask	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Paul A Mieyal	director	C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830